RECRUITINGPhase 3INTERVENTIONAL
Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
About This Trial
A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension
Who May Be Eligible (Plain English)
Who May Qualify:
- Adults aged 19 years and older
- Participants diagnosed with POAG or OH
- Have fully explained and understood the study and have voluntarily given written willing to sign a consent form.
Who Should NOT Join This Trial:
- Acute or chronic angle-closure glaucoma
- Congenital glaucoma, secondary glaucoma (open-angle glaucoma)
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Adults aged 19 years and older
* Participants diagnosed with POAG or OH
* Have fully explained and understood the study and have voluntarily given written informed consent.
Exclusion Criteria:
* Acute or chronic angle-closure glaucoma
* Congenital glaucoma, secondary glaucoma (open-angle glaucoma)
Treatments Being Tested
DRUG
HUC3-637
Ophthalmic solution instilled directly into the eye (topical ocular administration)
DRUG
HUC3-637-R
Ophthalmic solution instilled directly into the eye (topical ocular administration)
Locations (1)
Kangbuk Samsung Hospital
Seoul, South Korea